ABL Bio Inc.

KOSDAQ 298380.KQ

ABL Bio Inc. Revenue Per Share for the year ending December 31, 2023: USD 1.05

ABL Bio Inc. Revenue Per Share is USD 1.05 for the year ending December 31, 2023, a -5.87% change year over year. Revenue per share indicates revenue generated per share; higher ratios suggest stronger performance and value.

ABL Bio Inc. Revenue Per Share for the year ending December 31, 2022 was USD 1.12, a 1,076.38% change year over year.
ABL Bio Inc. Revenue Per Share for the year ending December 31, 2021 was USD 0.10, a -41.17% change year over year.
ABL Bio Inc. Revenue Per Share for the year ending December 31, 2020 was USD 0.16, a 112.42% change year over year.
ABL Bio Inc. Revenue Per Share for the year ending December 31, 2019 was USD 0.08, a 108.36% change year over year.

Key data

Date	Revenue Per Share	Dividend Per Share	Free Cash Flow Per Share	Return on Assets (ROA)

KOSDAQ: 298380.KQ

ABL Bio Inc.

CEO	Dr. Sang Hoon Lee Ph.D.
IPO Date	Dec. 19, 2018
Location	South Korea
Headquarters	16 Daewangpangyo-Ro 712 Beon-Gil
Employees	102
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline drugs include ABL001, cancer immunotherapy, ADC, and ABL301. The company is headquartered in Seongnam, South Korea.

Key trends

Past 5 years